Fifteen years of triple tests in The Netherlands; the life cycle of a screening test
E. J. Wortelboer, Maria P. H. Koster, Ph. Stoutenbeek, J.G. Loeber, G.H.A. Visser, Peter C. J. I. Schielen
Abstract
E. J. Wortelboer, Maria P. H. Koster, Ph. Stoutenbeek, J.G. Loeber, G.H.A. Visser, Peter C. J. I. Schielen
Abstract
OBJECTIVE: This report provides an overview of 15 years prenatal screening for Down syndrome (DS). METHODS: Between 1991 and 2005, blood samples for the triple test were sent for analysis to our laboratory. Test results were considered screen-positive for neural tube defects (NTDs) if the serum alpha-1-fetoprotein > or = 2.50 MoM for singleton pregnancies or screen-positive for DS if the calculated risk was at least 1 in 250. RESULTS: As many as 42 554 tests were performed. Data on the pregnancy outcome were available for 30 290 screening tests (71.2%). In 1991, most requests (93%) came from the university hospitals; thereafter a shift toward midwives occurred. Until 2001, the number of requests rose to 3500 a year. Most samples were collected between 15 and 17 weeks of gestation. The median age of women for whom a test was requested increased from 30.5 to 34.5. The detection rate (DR) for DS remained stable over the years (80%), with a false positive rate of about 13%. The DR for Trisomy 13, 18, and NTD was 50, 68, and 70%, respectively. CONCLUSION: Based on the results of this study, the triple test may be considered a fairly good second trimester screening test. Here it is shown that health practitioners got more acquainted with the test through the years. This may have served the swift introduction of a formal national screening program that started in January 2007.
OpenAlex reports 15 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
OBJECTIVE: This report provides an overview of 15 years prenatal screening for Down syndrome (DS). METHODS: Between 1991 and 2005, blood samples for the triple test were sent for analysis to our laboratory. Test results were considered screen-positive for neural tube defects (NTDs) if the serum alpha-1-fetoprotein > or = 2.50 MoM for singleton pregnancies or screen-positive for DS if the calculated risk was at least 1 in 250. RESULTS: As many as 42 554 tests were performed. Data on the pregnancy outcome were available for 30 290 screening tests (71.2%). In 1991, most requests (93%) came from the university hospitals; thereafter a shift toward midwives occurred. Until 2001, the number of requests rose to 3500 a year. Most samples were collected between 15 and 17 weeks of gestation. The median age of women for whom a test was requested increased from 30.5 to 34.5. The detection rate (DR) for DS remained stable over the years (80%), with a false positive rate of about 13%. The DR for Trisomy 13, 18, and NTD was 50, 68, and 70%, respectively. CONCLUSION: Based on the results of this study, the triple test may be considered a fairly good second trimester screening test. Here it is shown that health practitioners got more acquainted with the test through the years. This may have served the swift introduction of a formal national screening program that started in January 2007.
Key concepts: Triple test, Medicine, Down syndrome, Prenatal screening, Test (biology), Trisomy, Obstetrics, False positive rate